Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CMPX Stock Forecast 2026-2027
$2.03
Current Price
$365.58M
Market Cap
Buy 13
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CMPX Price Targets
+1,082.3%
To High Target of $24.00
+244.8%
To Median Target of $7.00
+97.0%
To Low Target of $4.00
CMPX Price Momentum
-0.5%
1 Week Change
+2.5%
1 Month Change
-15.8%
1 Year Change
-62.2%
Year-to-Date Change
-70.5%
From 52W High of $6.88
+26.1%
From 52W Low of $1.61
📊 TOP ANALYST CALLS
Did CMPX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Compass Therapeutics is one of their latest high-conviction picks.
Latest CMPX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CMPX has a bullish consensus with a median price target of $7.00 (ranging from $4.00 to $24.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $2.03, the median forecast implies a 244.8% upside. This outlook is supported by 13 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 1,082.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMPX Analyst Ratings
13
Buy
1
Hold
0
Sell
CMPX Price Target Range
Low
$4.00
Average
$7.00
High
$24.00
Current: $2.03
Latest CMPX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMPX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 28, 2026 | Canaccord Genuity | John Newman | Buy | Maintains | $7.00 |
| Apr 28, 2026 | Citizens | Reni J. Benjamin | Market Outperform | Reiterates | $10.00 |
| Apr 27, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $24.00 |
| Apr 27, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $30.00 |
| Mar 24, 2026 | Guggenheim | Buy | Reiterates | $N/A | |
| Jan 6, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 5, 2026 | William Blair | Outperform | Initiates | $N/A | |
| Dec 3, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Dec 3, 2025 | Citizens | Market Outperform | Initiates | $N/A | |
| Dec 3, 2025 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Nov 5, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 6, 2025 | LifeSci Capital | Outperform | Initiates | $N/A | |
| Aug 12, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 12, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Jul 1, 2025 | Raymond James | Sean McCutcheon | Outperform | Reinstates | $9.00 |
| May 9, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Apr 28, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 22, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 21, 2025 | D. Boral Capital | Buy | Maintains | $N/A |
Compass Therapeutics Inc. (CMPX) Competitors
The following stocks are similar to Compass Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CMPX
Compass Therapeutics
mkt cap
365.58M
Compass Therapeutics Inc. (CMPX) Financial Data
Compass Therapeutics Inc. has a market capitalization of $365.58M with a P/E ratio of -4.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -45.9%.
Valuation Metrics
Market Cap
$365.58M
Enterprise Value
$180.68M
P/E Ratio
-4.8x
PEG Ratio
0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+53.3%
Current Ratio
19.0x
Debt/Equity
5.3x
ROE
-45.9%
ROA
-27.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Compass Therapeutics Inc. (CMPX) Business Model
About Compass Therapeutics Inc.
What They Do
Develops proprietary antibody therapeutics for oncology.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on the development of antibody-based therapies that engage the immune system to treat cancer. It generates revenue through the advancement of its innovative product candidates, which are in various stages of clinical trials, potentially leading to partnerships, licensing deals, or product sales once they receive regulatory approval.
Additional Information
Founded in 2014 and based in Boston, Massachusetts, Compass Therapeutics is positioned in the competitive biopharmaceutical market with a strong emphasis on cancer immunotherapy. Its unique technology platform includes advanced antibody discovery and manufacturing capabilities, aiming to address significant unmet medical needs within oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
39
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Country
United States
IPO Year
2021
Website
www.compasstherapeutics.comCompass Therapeutics Inc. (CMPX) Latest News & Analysis
Latest News
Quick Summary
Compass Therapeutics (NASDAQ: CMPX) is preparing for a crucial FDA meeting regarding tovecimig, its DLL4/VEGF bispecific antibody, following positive randomized study results in advanced biliary tract cancer.
Why It Matters
Positive results from the study and an upcoming FDA meeting for tovecimig could lead to potential approval, impacting Compass Therapeutics' stock value and market position significantly.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Compass Therapeutics, Inc. (CMPX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting key developments and future plans in their healthcare initiatives.
Why It Matters
Compass Therapeutics' presentation at a prestigious healthcare conference signals potential insights into its pipeline, investor interest, and market positioning, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) will participate in several investor events in June 2026, focusing on its oncology-focused antibody-based therapeutics.
Why It Matters
Compass Therapeutics’ participation in investor events signals potential visibility and interest in its oncology developments, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). Interested investors can contact Danielle Peyton for more information.
Why It Matters
The investigation into Compass Therapeutics may indicate potential legal issues or irregularities, impacting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Compass Therapeutics (Nasdaq: CMPX) will present Phase 1 study data for CTX-8371, a PD-1×PD-L1 bispecific antibody, at the ASCO Annual Meeting from May 29 to June 2, 2026.
Why It Matters
The upcoming ASCO presentation of CTX-8371 data could influence Compass Therapeutics' stock price, reflecting investor confidence in its potential as a cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) will participate in several investor events in May 2026, focusing on its development of antibody-based therapeutics for oncology.
Why It Matters
Compass Therapeutics' participation in investor events indicates potential for increased visibility and engagement, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CMPX Stock
What is Compass Therapeutics Inc.'s (CMPX) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Compass Therapeutics Inc. (CMPX) has a median price target of $7.00. The highest price target is $24.00 and the lowest is $4.00.
Is CMPX stock a good investment in 2026?
According to current analyst ratings, CMPX has 13 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMPX stock?
Wall Street analysts predict CMPX stock could reach $7.00 in the next 12 months. This represents a 244.8% increase from the current price of $2.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compass Therapeutics Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on the development of antibody-based therapies that engage the immune system to treat cancer. It generates revenue through the advancement of its innovative product candidates, which are in various stages of clinical trials, potentially leading to partnerships, licensing deals, or product sales once they receive regulatory approval.
What is the highest forecasted price for CMPX Compass Therapeutics Inc.?
The highest price target for CMPX is $24.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 1,082.3% increase from the current price of $2.03.
What is the lowest forecasted price for CMPX Compass Therapeutics Inc.?
The lowest price target for CMPX is $4.00 from at , which represents a 97.0% increase from the current price of $2.03.
What is the overall CMPX consensus from analysts for Compass Therapeutics Inc.?
The overall analyst consensus for CMPX is bullish. Out of 6 Wall Street analysts, 13 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CMPX stock price projections?
Stock price projections, including those for Compass Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 6:01 AM UTC